TG Therapeutics, Inc. announced today the initiation of a multi-center, Phase I trial to evaluate the safety and efficacy of the combination of TGR-1202 and ibrutinib for patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL):
TGR-1202 is a PI3k-delta inhibitor similar to Gilead's Idelalisib. They also have TG-1102, which a glico- (sugar) shrouded anti-CD20 monoclonal anti-body being tested with Ibrutinib. It's sort of a souped up, 3rd generation Rituxan. Supposedly more efficient at lower dosage and hence less side effects.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.